|
業務類別
|
Biotechnology |
|
業務概覽
|
Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases. |
| 公司地址
| 77 Sir John Rogerson’s Quay, Block C, Grand Canal Docklands, Dublin 2, Dublin, IRL, D02 VK60 |
| 電話號碼
| +353 12362500 |
| 傳真號碼
| +353 19023510 |
| 公司網頁
| https://www.prothena.com |
| 員工數量
| 67 |
| Mr. Brandon S. Smith |
Chief Operating Officer |
美元 540.71K |
27/02/2026 |
| Mr. Michael J. Malecek |
Chief Legal Officer and Company Secretary |
-- |
27/02/2026 |
| Dr. Wagner M. Zago, PhD |
Chief Scientific Officer |
美元 514.22K |
27/02/2026 |
| Dr. Gene G. Kinney, PhD |
Director, President and Chief Executive Officer |
美元 692.97K |
27/03/2026 |
| Ms. Karin L. Walker |
Chief Accounting Officer |
-- |
27/02/2026 |
| Mr. Chad J. Swanson |
Chief Development Officer |
美元 516.67K |
27/02/2026 |
| Mr. Tran B. Nguyen |
Chief Strategy Officer and Chief Financial Officer |
美元 600.39K |
27/02/2026 |
|
|
| Dr. William H. Dunn, Jr |
Independent Director |
27/03/2026 |
| Dr. Gene G. Kinney, PhD |
Director, President and Chief Executive Officer |
27/03/2026 |
| Mr. Daniel G. Welch |
Chairman of the Board |
27/03/2026 |
| Mr. Shane M. Cooke |
Independent Director |
27/03/2026 |
| Dr. Lars G. Ekman, M.D.,PhD |
Chairman Emeritus and Director |
27/03/2026 |
| Dr. Dennis J. Selkoe, M.D. |
Independent Director |
27/03/2026 |
| Mr. Richard T. Collier |
Independent Director |
27/03/2026 |
| Ms. Helen S. Kim |
Independent Director |
27/03/2026 |
|
|
|
|
